Sanofi India Recommends Final Dividend of ₹48, Total Dividend ₹123 for FY25
Sanofi India's Board approved FY25 audited results and recommended a final dividend of ₹48, bringing the total dividend to ₹123 per share. The company appointed Mrs. Rajani Kesari as Independent Director and Ms. Sudipta Chakraborty as Whole-time Director. Mr. Rodolfo Hrosz resigned as Non-Executive Director.
The dividend announcement and key management changes are material to the company's governance and shareholder returns, impacting investor sentiment and strategic direction.
The announcement is positive due to the recommendation of a significant final dividend and key management appointments, indicating stability and growth prospects.
Sanofi India Limited announced the outcome of its Board Meeting held on February 25, 2026. The Board considered and approved the Audited Financial Results for the Quarter and Financial Year ended December 31, 2025. The company reported an unmodified audit opinion from its statutory auditors, M/s Price Waterhouse & Co. Chartered Accountants LLP, for the Financial Year ended December 31, 2025.
Furthermore, the Board recommended a final dividend of ₹48 per equity share of face value ₹10. This is in addition to the interim dividend of ₹75 per equity share declared on October 29, 2025. The total dividend for the financial year 2025 amounts to ₹123 per equity share, subject to shareholder approval at the ensuing 70th Annual General Meeting.
The Board also approved several changes in directorships. Mrs. Rajani Kesari has been appointed as an Additional Director and Independent Director for a term of 5 years effective April 1, 2026. Mr. Rodolfo Hrosz resigned as Non-Executive Director effective February 28, 2026. Ms. Sudipta Chakraborty has been appointed as an Additional Director and Whole-time Director for a term of 3 years effective March 1, 2026, and will also be designated as Key Managerial Personnel and Senior Management Personnel.
The financial results for the year ended December 31, 2025, show Total Income of ₹18,571 crore and Profit Before Tax of ₹4,447 crore. For the quarter ended December 31, 2025, Total Income was ₹4,226 crore and Profit Before Tax was ₹830 crore.
The Board meeting commenced at 2:00 p.m. and concluded at 5:30 p.m.
What to do with a filing like this
Sanofi India Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sanofi India Limited. Read the original for the full detail.